Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases

Seyed Seyed Mousavi Tasieh, PE Verweij, Johan Mouton

Research output: Contribution to journalArticleAcademicpeer-review

38 Citations (Scopus)

Abstract

The prodrug isavuconazonium sulfate (BAL8557) is an extended-spectrum water-soluble triazole, developed for the treatment of severe invasive and life-threatening fungal diseases. Its active moiety, BAL4815, is a potent inhibitor of ergosterol biosynthesis, resulting in the disruption of fungal membrane structure and function. The active compound shows broad-spectrum of activity and potency against all major opportunistic fungi, such as Aspergillus spp., Candida spp., Cryptococcus spp., Mucorales, Black yeasts and their filamentous relatives and the true pathogenic fungi, including Histoplasma capsulatum and Blastomyces dermatitidis. It is currently in Phase III clinical development for treatment of aspergillosis, candidiasis and mucormycosis, as well as other rare fungi infections. We reviewed the pharmacokinetic and pharmacodynamic characteristics of isavuconazole, and its microbiological and clinical investigation progress in advanced stages of development.
Original languageUndefined/Unknown
Pages (from-to)9-27
Number of pages19
JournalExpert Review of Anti-Infective Therapy
Volume13
Issue number1
DOIs
Publication statusPublished - 2015

Cite this